X0508 4 2024-01-02 0 0001649094 Vaxcyte, Inc. PCVX 0001918033 Eydelman Mikhail C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, SUITE 300 SAN CARLOS CA 94070 0 1 0 0 SVP, Gen Counsel & Corp Sec 1 Common Stock 2024-01-02 4 M 0 1667 21.41 A 22377 D Common Stock 2024-01-02 4 S 0 141 62.912 D 22236 D Common Stock 2024-01-02 4 S 0 598 63.593 D 21638 D Common Stock 2024-01-02 4 S 0 928 64.31 D 20710 D Stock Option (right to buy) 21.41 2024-01-02 4 M 0 1667 0.00 A 2032-05-08 Common Stock 1667 193333 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $63.13 to $64.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $64.13 to $65.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Mikhail Eydelman, by /s/ Ron A. Metzger, Attorney-in-Fact 2024-01-04